A detailed history of Aquilo Capital Management, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Aquilo Capital Management, LLC holds 428,766 shares of ARVN stock, worth $11.5 Million. This represents 11.41% of its overall portfolio holdings.

Number of Shares
428,766
Previous 405,766 5.67%
Holding current value
$11.5 Million
Previous $16.8 Million 31.86%
% of portfolio
11.41%
Previous 13.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.46 - $40.4 $562,580 - $929,200
23,000 Added 5.67%
428,766 $11.4 Million
Q1 2024

May 15, 2024

SELL
$36.38 - $52.31 $3.03 Million - $4.36 Million
-83,387 Reduced 17.05%
405,766 $16.8 Million
Q3 2023

Nov 14, 2023

SELL
$19.64 - $28.21 $2.65 Million - $3.8 Million
-134,788 Reduced 21.6%
489,153 $9.61 Million
Q2 2023

Aug 14, 2023

SELL
$21.73 - $31.43 $108,650 - $157,150
-5,000 Reduced 0.79%
623,941 $15.5 Million
Q1 2023

May 15, 2023

SELL
$26.15 - $37.26 $1.18 Million - $1.68 Million
-45,000 Reduced 6.68%
628,941 $17.2 Million
Q4 2022

Feb 14, 2023

BUY
$32.47 - $57.24 $71,304 - $125,699
2,196 Added 0.33%
673,941 $23.1 Million
Q3 2022

Nov 14, 2022

SELL
$41.87 - $57.99 $4.19 Million - $5.8 Million
-100,000 Reduced 12.96%
671,745 $29.9 Million
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $2.75 Million - $5.68 Million
76,498 Added 11.0%
771,745 $32.5 Million
Q1 2022

May 16, 2022

BUY
$60.27 - $81.57 $7.94 Million - $10.8 Million
131,796 Added 23.39%
695,247 $46.8 Million
Q4 2021

Feb 14, 2022

BUY
$65.85 - $96.21 $13.7 Million - $20.1 Million
208,740 Added 58.85%
563,451 $46.3 Million
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $26 Million - $38.3 Million
354,711 New
354,711 $29.2 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.43B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Aquilo Capital Management, LLC Portfolio

Follow Aquilo Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aquilo Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aquilo Capital Management, LLC with notifications on news.